Biotech Stock Roundup: ALXN, ACOR Drugs' Get FDA Nod, AGEN Up On GILD Deal
Zacks Investment Research | Dec 25, 2018 09:34PM ET
It was a busy week for the biotech sector with regulatory updates. The FDA approved Alexion’s the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here .
Acorda Gets FDA Nod ForParkinson's Disease Drug: Acorda announced that the FDA has approved its Parkinson's disease (PD) drug Inbrija (levodopa inhalation powder). The product was approved for treating OFF periods (return of Parkinson’s symptoms that result from low levels of dopamine between doses of oral carbidopa/levodopa) in PD patients, who are receiving carbidopa / levodopa regimen. Inbrija is expected to be launched during the first quarter of 2019. The FDA was expected to make its decision on Inbrija in October. However, in September the FDA delayed its verdict by three months and set an action date of Jan 5, 2019. The FDA approval thus comes slightly earlier than expected.
FDA Approves Stemline’s Drug: Stemline Therapeutics, Inc (NASDAQ:STML) received FDA approval for its CD123-targeted therapy, Elzonris (tagraxofusp-erzs; SL-401) for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adult and pediatric patients two years and older, in both treatment-naïve and previously treated populations. The therapy will be available in early 2019. BPDCN is an aggressive hematologic malignancy. The therapy is also under review in the United States.
Performance
Medical - Biomedical and Genetics Industry 5YR % Return
Biotech Stock Roundup: Pipeline Updates From VRTX & AMGN, ADRO Teams Up With LLY )
What's Next in Biotech?
Stay tuned for more regulatory and pipeline updates.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
Get The News You Want
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.